Skip to main content

Table 1 Demographic and clinical characteristics of patients with axSpA participating in exercise therapy

From: Clinical improvement and reduction in serum calprotectin levels after an intensive exercise programme for patients with ankylosing spondylitis and non-radiographic axial spondyloarthritis

  All (n = 40) AS (n = 22) nr-axSpA (n = 18) P value
Age, years 36.78 ± 1.09 36.91 ± 1.16 36.61 ± 2.03 ns
Gender (% female) 32.5 18.2 50.0 0.05
BMI at baseline 25.25 ± 0.44 25.51 ± 0.76 25.02 ± 0.50 ns
Disease duration since first symptoms (years) 9.94 ± 1.31 12.27 ± 1.42 7.10 ± 2.19 ˂0.001
Disease duration since diagnosis (years) 4.03 ± 0.75 5.84 ± 1.17 1.81 ± 0.52 ˂0.01
HLA-B27 positivity (%) 90.0 90.9 88.8 ns
History of uveitis/exacerbation (%)a 35.0/7.5 27.7/9.1 44.4/5.5 ns
History of peripheral arthritis/exacerbation (%)a 42.5/2.5 45.5/4.5 38.9/0 ns
Hip involvement (%) 17.5% 22.7% 11.1% ns
Therapy - NSA (daily use/on demand) (%) 100 (27.5/72.5) 100 (18.2/81.8) 100 (38.9/61.1) ns
NSA changes during exercise therapy/changes to daily use (%) 7.5/2.5 0/0 16.7/5.5 ns
Therapy - sulfasalazin (%) 10.0 4.5 16.6 ns
Therapy – biological agents (%)b 5.0 9.0 0 ns
Smokers ever/current 25.0/20.0 31.8/27.3 22.2/16.7 ns
  1. aExacerbations of uveitis/arthritis occurred during exercise intervention. No extraarticular signs other than uveitis were manifested. bOnly tumour necrosis factor alpha inhibitors (TNFi) were used in long-term therapy for high disease activity. Statistical analysis: p value was calculated for comparison between the ankylosing spondylitis (AS) and the axial non-radiographic spondyloarthritis (nr-axSpA) group using either the Mann-Whitney test or chi-squared/Fisher´s exact test. Data are characterised as mean ± standard deviation unless stated otherwise. axSpA axial spondyloarthritis, BMI body mass index, NSA non-steroidal antirheumatic drugs, ns not significant